AVXL — Anavex Life Sciences Corp.
$1.33-2.21%
Last close: · regular session
After-hours $1.29 -3.01% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for AVXL in the TickerWise workspace.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 42
- Website: https://www.anavex.com
Latest SEC filings for AVXL
Latest AVXL news
- ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL Read article
- AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm Read article
- ROSEN, RECOGNIZED TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL Read article
- Anavex Life Sciences gains IND clearance for blarcamesine in Fragile X syndrome Read article
- Kaplan Fox Advises Anavex Life Sciences Corp. (AVXL) Investors to Act Before the Lead Plaintiff Deadline on November 30, 2026 Read article
- AVXL Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corp. Class Action Lawsuit Read article
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL Read article
- DEADLINE ALERT for QFIN, DAVA, AVXL, GOOGL: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.